Dual Bclxl and BCL2 Inhibition with Navitoclax (NAV), Venetoclax (VEN), and Decitabine (DEC) for Advanced Myeloid Neoplasms (MN): Safety and Biological Activity in a Phase 1 Study
Evan C. Chen(Dana-Farber Cancer Institute), Jacqueline S. Garcia(Dana-Farber Cancer Institute), Karen Quillen(Boston University), Eric S. Winer(Providence College), Maximilian Stahl(Harvard University), Anthony Letai(Dana-Farber Cancer Institute), Marlise R. Luskin(Dana-Farber Cancer Institute), Rebecca Leonard(Dana-Farber Cancer Institute), Rahul S. Vedula(Harvard University), Ilene Galinsky(Dana-Farber Cancer Institute), Jeremy Ryan(Dana-Farber Cancer Institute), Hayden L. Bell(Newcastle University), Virginia O. Volpe(UConn Health), Andrew A. Lane(Dana-Farber Cancer Institute), Richard M. Stone(Dana-Farber Cancer Institute), Daniel J. DeAngelo(Dana-Farber Cancer Institute), Yiwen Liu(University of Arizona), Emma-Jayne Minihane(Dana-Farber Cancer Institute), Matthew Hersch(Dana-Farber Cancer Institute), Donna Neuberg(Otsuka (Japan))
Cited by 3
Related Papers
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k